References
- Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73
- Kimball AB, Jacobson C, Weiss S, et al. The psychological burden of psoriasis. Am J Clin Dermatol. 2005;6:383–92
- Gisondi P, Girolomoni G, Sampogna F, et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol. 2005;15:279–83
- Pariser DM, Bagel J, Gelfand JM, et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143:239–42
- Hsu S, Papp KA, Leb MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102
- Sistema Nazionale Linee Guida ISS-Associazione Dermatologi Ospedalieri Italiani. Il trattamento della Psoriasi nell’adulto (2013). Available from http://www.snlg-iss.it/cms/files/LG_Psoriasi.pdf. Accessed September 11, 2013
- Colombo GL, Di Matteo S, Peris K, et al. A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. Clinicoecon Outcomes Res. 2009;1:53–9
- Ahn CS, Gustafson CJ, Sandoval LF, et al. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14:315–26
- Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2011;25:2–11
- Katz KA. ‘Biologics': a clinically meaningless term. Br J Dermatol. 2006;154:809–12
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509
- Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNF rapidly reduces density of dendritic cells and macrofages in psoriatic plaques with restoration of epidermal keratinocites differentiation. J Dermatol Sci. 2007;48:87–101
- Stata Corp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2010
- Altobelli E, Marziliano C, Fargnoli MC, et al. Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. J Eur Acad Dermatol Venereol. 2012;26:976–82
- Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity to clinical response to systemic treatment for psoriasis. Evidence from the Psocare Project. Dermatology. 2008;217:365–73
- Psocare: valutazione degli esiti dei trattamenti per la psoriasi in Italia. Un programma di ricerca promosso dall’Agenzia Italiana del Farmaco in collaborazione con società scientifiche e associazioni dei pazienti. Bollettino di Informazione sui Farmaci 2004; anno XI, n.5–6:189–93
- Istituto Nazionale di Statistica (ISTAT). Condizioni di salute, fattori di rischio e ricorso ai servizi sanitari. Anno 2005
- DOXA – Istituto Superiore di Sanità. Il fumo in Italia. 2008
- Prignano F, Pescitelli L, Ricceri F, Lotti T. Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. J Eur Acad Dermatol Venereol. 2010;24:555–60
- Gisondi P, Cazzaniga S, Chimenti S, et al.; Psocare Study Group. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27:e30–41
- Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol. 2002;138:337–42